Complete Response of a Recurrent, Multicentric Malignant Glioma in a Patient Treated with Phenylbutyrate
Sodium phenylbutyrate is a biological-response modifier that acts as a dose-dependent inhibitor of glioma cell proliferation, migration, and invasiveness in vitro, possibly by inhibition of urokinase and c-myc pathways. Despite its biological activity in vitro, there have not been any prior reports of efficacy in the treatment of human malignant gliomas.
We report a 44-year-old female with a recurrent, multicentric, malignant glioma who experienced a durable remission lasting more than four years. The patient initially presented with seizures caused by a biopsy-proven anaplastic astrocytoma of the frontal lobe. The patient was treated with radiation therapy and Procarbazine–CCNU–Vincristine (PCV). However, the tumor progressed and extended to the corpus callosum with midline shift, refractory to four cycles of continuous 72-h infusion of BCNU/Cisplatinum. Additional enhancing lesions appeared in the left frontal and left temporal lobes. The patient was started on sodium phenylbutyrate, 18 g daily in three divided oral doses, and reduced to 9 g/day and eventually to 4.5 g/day to eliminate mild, reversible side effects. Four years later, the patient has a KPS functional score of 100%. Phenylbutyrate is a well-tolerated, oral agent that shows potential for the treatment of malignant gliomas. Further studies should be considered to identify a subset of patients that have tumors sensitive to phenylbutyrate, either as a single agent or in combination with radiation therapy or other chemotherapeutic agents.
Unable to display preview. Download preview PDF.
- 1.Davis FG, Freels S, Grutsch J, Barlas S, Brem S: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg 88: 1–10, 1998Google Scholar
- 2.Andratschke N, Grosu AL, Molls M, Nieder C: Perspectives in the treatment of malignant gliomas in adults. Anticancer Res 21(5): 3541–3550, 2001Google Scholar
- 3.Grossman SA, Fisher JD, Piantadosi S, Brem H: The New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: organization, objectives, and activities. Cancer Control 5(2): 107–114, 1998Google Scholar
- 4.Engelhard HH, Homer RJ, Duncan HA, Rozental J: Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells. J Neuro-Oncol 37(2): 97–108, 1998Google Scholar
- 5.Fisher JD, Carducci, MA, Baker SD, Phuphanich S, Grossman SA, Gilbert M, Piantadosi, NABTT CNS Consortium: Dose escalation study of oral sodium phenylbutyrate in patients with refractory high grade astrocytomas: maximum tolerated dose, toxicity profile, pharmacology, and survival. Proc Am Soc Clin Oncol 19: 166a, 2000Google Scholar
- 6.Gore SD, Samid D, Weng LJ: Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res 3(10): 1755–1762, 1997Google Scholar
- 7.Ram Z, Samid D, Walbridge S, Oshiro EM, Viola JJ, Tao-Cheng JH, Shack S, Thibault A, Myers CE, Oldfield EH: Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. Cancer Res 54: 2923–2927, 1994Google Scholar
- 8.Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE: Phase I study of phenylacetate administration twice daily to patients with cancer. Cancer 75: 2932–2938, 1995Google Scholar
- 9.Samid D, Hudgins WR, Shack S, Liu L, Prasanna P, Myers CE: Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv Exp Med Biol 400A: 501–505, 1997Google Scholar
- 10.Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Schiff D, Gilbert M, Rankin C, Prados MD: Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 17(3): 984–990, 1999Google Scholar
- 11.Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames MM, Tong WP, Lim S, Figg WD: Phase II study of antineoplastons A10 (NSC 648539) and AS2–1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 74(6): 641–642, 1999Google Scholar
- 12.Samid D, Ram Z, Hudgins WR, Shack S, Liu L, Walbridge S, Oldfield EH, Myers CE: Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res 54: 891–895, 1994Google Scholar
- 13.Witzig TE, Timm M, Stenson M, Svingen PA, Kaufmann SH: Induction of apoptosis in malignant B cells by phenylbutyrate or phenyl acetate in combination with chemotherapeutic agents. Clin Cancer Res 6(2): 681–692, 2000Google Scholar
- 14.Pomeroy SL, Tamayo P, Gaasenbeek M et al.: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436–442, 2002Google Scholar
- 15.Brem S: Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control 6: 436–458, 1999Google Scholar